Skip to main content
. 2019 Jul 17;11(7):1635. doi: 10.3390/nu11071635

Figure 1.

Figure 1

Flow-chart describing the inclusion process of the 28 irritable bowel syndrome (IBS) patients completing the six-week trial and included in the analysis.